OBJECTIVE: To probe into the efficacy of internal iliac artery transcatheter arterial chemoembolization（TACE） with gemcitabine combined with cisplatin（GP） and gemcitabine combined with lobaplatin（GL） in the treatment of muscle invasive bladder urothelial carcinoma. METHODS: A total of 104 patients with invasive bladder urothelial carcinoma admitted into the hospital from Jan. 2019 to Jan. 2021 were extracted to be divided into the observation group and the control group via the random number table. Two groups were treated with TACE

52 patients in the control group were treated with GP regimen

and 52 patients in the observation group received GL regimen. The clinical efficacy and adverse drug reactions

tumor markers

inflammatory response and immune function before and after treatment were compared between two groups. RESULTS: The disease control rate of the observation group was 71.15%（37/52）

higher than 51.92%（27/52） of the control group

with statistically significant differences（P

<

0.05）. After treatment

the serum levels of CA125 and CEA in the observation group were lower than those in the control group

the serum levels of interleukin（IL）6

IL-1β and TNF-α were lower than those of the control group

and CD3

+

CD4

+

and CD4

+

/CD8

+

were higher than those of the control group

the differences were statistically significant（P

<

0.05）. The incidences of bone marrow suppression

leukopenia

nausea and vomiting in the observation group were respectively 11.54%（6/52）

38.46%（20/52） and 26.92%（14/52）

lower than 26.92%（14/52）

59.62%（31/52） and 48.08%（25/52） in the control group

the differences were statistically significant（P

<

0.05）. CONCLUSIONS: GL regimen TACE treatment can improve the level of tumor markers in patients with invasive bladder urothelial carcinoma

alleviate inflammatory response

regulate immune function and reduce adverse drug reactions with definite clinical efficacy.